BioCentury | May 30, 2020
Tools & Techniques

Denali offers rare peek into the science behind its CNS delivery platform

Denali is lifting the veil on the delivery technology it’s using to transport large molecules into the CNS, detailing a differentiated strategy for hijacking the transferrin receptor. The company revealed features of its large molecule...
BC Week In Review | Jun 1, 2018
Company News

Denali opts in for F-star's Fcabs

Neurodegenerative company Denali Therapeutics Inc. (NASDAQ:DNLI) has exercised an option to acquire F-star Gamma Ltd., an asset-centric subsidiary of F-star Biotechnology Ltd. (Cambridge, U.K.). The deal gives Denali rights to Fcabs against blood-brain barrier (BBB)...
BC Extra | May 30, 2018
Company News

Denali opts in for F-star's Fcabs

Neurodegenerative company Denali Therapeutics Inc. (NASDAQ:DNLI) has exercised an option to acquire F-star Gamma Ltd., an asset-centric subsidiary of F-star Biotechnology Ltd. (Cambridge, U.K.). The deal gives Denali rights to Fcabs against blood-brain barrier (BBB)...
BC Week In Review | Nov 17, 2017
Financial News

Neurology play Denali planning $100M IPO

According to an SEC filing, neurodegenerative disease company Denali Therapeutics Inc. (South San Francisco, Calif.) is seeking to raise $100 million in an IPO on NASDAQ. Goldman Sachs, Morgan Stanley, JPMorgan and Evercore are underwriting...
BC Extra | Nov 15, 2017
Financial News

Neurology play Denali planning $100M IPO

According to an SEC filing , neurodegenerative disease company Denali Therapeutics Inc. (South San Francisco, Calif.) is seeking to raise $100 million in an IPO on NASDAQ. Goldman Sachs, Morgan Stanley, JPMorgan and Evercore are underwriting...
Items per page:
1 - 5 of 5